Journal of Oncology

Journal of Oncology / 2017 / Article

Review Article | Open Access

Volume 2017 |Article ID 1532534 |

Alexandru Filippi, Oana-Alina Ciolac, Constanța Ganea, Maria-Magdalena Mocanu, "ErbB Proteins as Molecular Target of Dietary Phytochemicals in Malignant Diseases", Journal of Oncology, vol. 2017, Article ID 1532534, 20 pages, 2017.

ErbB Proteins as Molecular Target of Dietary Phytochemicals in Malignant Diseases

Academic Editor: Stefano Cascinu
Received28 Oct 2016
Revised30 Dec 2016
Accepted17 Jan 2017
Published13 Feb 2017


ErbB proteins overexpression, in both normal and mutated forms, is associated with invasive forms of cancer prone to metastasis and with stronger antiapoptotic mechanisms and therefore more challenging to treat. Downstream effectors of ErbB receptors mediating these phenotypic traits include MAPK, STAT, and PI3K/AKT/mTOR pathways. Various phytochemical compounds were studied for their large number of biological effects including anticancer activity. Among these compounds, epigallocatechin-3-gallate (EGCG), the main catechin from green tea leaves, and curcumin, component of the curry powder, constituted the object of numerous studies. Both compounds were shown to act directly either on ErbB expression, or on their downstream signaling molecules. In this paper we aim to review the involvement of ErbB proteins in cancer as well as the biologic activity of EGCG and curcumin in ErbB expressing and overexpressing malignancies. The problems arising in the administration of the two compounds due to their reduced bioavailability when orally administered, as well as the progress made in this field, from using novel formulations to improved dosing regimens or improved synthetic analogs, are also discussed.

1. Introduction

ErbB proteins are part of the receptor tyrosine kinases family and include four members ErbB1 (also known as EGFR, HER1), ErbB2 (Neu, HER2), ErbB3 (HER3), and ErbB4 (HER4). Since the discovery of the first ErbB protein three decades ago, all four members were shown to be involved in cancer when mutated or overexpressed [1]. ErbB positive cancers are generally associated with a poor prognostic [2, 3], as ErbB overexpression promotes the migration and invasion of cancer cells [4]. Such actions are mediated through the activation of multiple signaling cascades such as MAPK pathway, Akt, and phospholipase Cγ which lead to the overexpression of several protooncogenic transcription factors [5]. All ErbB receptors can form homo- or heterodimers. Depending on the expression levels, ErbB1 receptors might be present mainly in monomeric form at low expression levels, while ErbB2 receptors are usually found predominantly in aggregates of 3 to 8 molecules [6].

ErbB proteins are used now as molecular markers in therapy, since they can be targeted with either tyrosine kinase inhibitors or with specific monoclonal antibodies, for example, cetuximab and panitumumab against ErbB1 or trastuzumab and pertuzumab against ErbB2 [7, 8]. In spite of the significant success with the use of the monoclonal antibodies in the therapy of ErbB overexpressing cancers, their activity was hindered by the treatment resistance. The resistance to ErbB antibodies may be caused by nuclear localization of ErbB2 [9], miRNA production [10], higher Akt signaling, or steric hindrance by other membrane proteins [11] and raises the need for other therapeutic compounds useful in the treatment of ErbB overexpressing cancers.

Curcumin, a phytochemical constituent of Curcuma longa, used in traditional Ayurveda medicine, is now intensively studied due to its anti-inflammatory [12], antitumor [13], and anti-infectious [14] actions. EGCG is the most active and abundant catechin found in Camellia sinensis leaves, representing about 16.5% by weight of the water extractable fraction of green tea plants [15]. Among the many actions that EGCG has been shown to exert, are protection against cardiovascular disease [16] and antioxidative [16, 17], antiviral, antibacterial and antifungal [18], and antitumor activities [19]. Both curcumin [20] and EGCG [21] were shown to decrease ErbB2 expression and phosphorylation as well as downstream signaling molecules involved in survival and proliferation of the cancer cells.

2. ErbB Proteins and Cancer

ErbB proteins are tyrosine kinase (TK) receptors localized at the plasma membrane level. Up to now, their family includes four members: ErbB1 to ErbB4 and their name was originated from the discovery of avian erythroblastosis viral protein which encoded an abnormal form of epidermal growth factor receptor (EGFR) [5, 22, 23]. A parallel nomenclature for ErbB family frequently used in the scientific field is human epidermal growth factor receptors, HER1 to HER4 [24]. Additionally, a mutated form of ErbB2 has been identified in a chemical induced rodent neuroblastoma and the nucleotide sequence able to produce transformation was named Neu [25, 26]. However, in human breast or gastric cancer ErbB2 gene was found rather amplified and not mutated [2729]. The genes responsible for ErbB family production are part of the four homebox (Hox) clusters localized on different chromosomes (Table 1) [7, 30]. The physiological role of ErbB proteins was investigated in several mouse models. The absence of ErbB1 gene in mouse models was associated with respiratory, gastrointestinal, and skin problems [3134] and the lack of ErbB2 gene in mouse models or the therapy against ErbB2 was accompanied by the heart failure [3537].

ErbB member
Genomic locationMolecular mass (kDa)Number of amino acids

ErbB1Chromosome 71341210
ErbB2Chromosome 171381255
ErbB3Chromosome 121481342
ErbB4Chromosome 2147

Each family member has three main domains: the ligand binding domain, the transmembrane domain, and the kinase domain [38]. The crystal structure of the extracellular/ligand binding domain displayed ligand binding cleft only for three of the family members: ErbB1, ErbB3, and ErbB4, while ErbB2 has no ligand binding cleft [3842]. For this reason ErbB2 is considered an orphan receptor since it has no ligand and it has a constitutive conformation which was shown to be similar to the activated form of the receptors [8, 43]. The extracellular domain consists of four regions (I to IV) with different functions: I and III are responsible for ligand binding, and region II after ligand binding extends the dimerization arm, while the interaction between region II and IV maintains the extracellular domain in a tethered/inactive form [8].

The reported number of ErbB ligands increased to 11, namely, amphiregulin (AR), betacellulin (BCT), epidermal growth factor (EGF), epigen (EPG), epiregulin (EPR), heparin-binding EGF (HB-EGF), transforming growth factor alpha (TGFα), neuregulin- (NRG-) 1 to neuregulin-4 [5, 7, 38]. A family of proteases, disintegrin, and metalloproteases (ADAMs) are responsible for generation of ErbB family ligands, which are released by ectodomain shedding from single-pass membrane precursor proteins [44, 45]. The number of amino acid residues responsible for binding ErbB receptors varies from 53 amino acids in case of EGF to 359 amino acids in case of NRG-3 [7]. Up to now, a clear identification of which ligand binds to which ErbB homo- or heterodimer might be a complex task, since 11 ligands can bind 28 possible dimer combinations leading to more than 600 assortments [7]. However, a schematic version of ligand binding to ErbB receptors was depicted in Figure 1 [5, 7]. After the ligand binding, homo- or heterodimerization of ErbB receptors takes place followed by activation of the intracellular kinase domain and by triggering of the numerous intracellular signaling pathways.

Two of the ErbB proteins have incomplete capacity to trigger the intracellular signaling: ErbB2 is an orphan receptor, while ErbB3 has no intrinsic kinase activity. However, the combination ErbB2-ErbB3 was shown to be the most mitogenic one compared to the other dimers of ErbB family [5, 8]. The overexpression of ErbB2 protein in cancer cells made from this member of the family one of the preferred partners for heterodimerization; if there are not enough ErbB family partners on the surface of the cells, ErbB2 can form spontaneously homodimers [5]. Synchronized activation of phosphatidylinositol 3-kinase (PI3K)/Akt pathway, the mitogen-activated protein kinase (MAPK) pathway, phospholipase Cγ (PLCγ), activation of Src kinase, signal transducer, and activator of transcription (STAT) pathway had been associated with increased cell division, survival, migration, differentiation, and inhibition of apoptosis [5]. Furthermore, cross-talking between ErbB signaling pathways and the estrogen receptors (ER), vascular endothelial growth factor (VEGF), insulin growth factor receptor (IGFR), and integrins pathways has been reported [4650].

At the surface of the cancer cells, ErbB proteins are regularly overexpressed: at about two millions of EGFR in A-431 human epidermoid carcinoma cells and 105-106 ErbB2 proteins in SK-BR-3 breast cancer cell line [51, 52]. The overexpression of ErbB proteins in different cancer types: lung (overexpression of EGFR in 60% of non-small-cell lung cancer, NSCLC), breast (overexpression of ErbB2 in 20–30% of breast cancer), gastric (overexpression of ErbB2 in 22% of gastric cancer), or colorectal cancer (overexpression of EGFR in 25 to 82% of colorectal cancer) made them an attractive therapeutic target [27, 5356].

The first molecules known to inhibit the activity of ErbB proteins (mainly EGFR and ErbB2) have been the antibodies, followed by small inhibitors of the TK domains [38]. One of the antibodies used to target EGFR had been the following: Erbitux (cetuximab) with antiproliferative activity and the ability to block the cell cycle in G1 phase; until now Erbitux has been used in the therapy of colorectal cancer (CRC) and clinical trials are in progress for pancreatic cancer, head and neck squamous cell carcinoma, or NSCLC [8, 57]. Matuzumab and panitumumab are two other monoclonal antibodies which can block EGFR activity; the antibodies are able to inhibit ligand-mediated activation followed by reduced EGFR signaling, cell cycle arrest, and reduced angiogenesis; clinical trials are in progress for CRC and NSCLC [8, 58, 59]. The activation of ErbB2 oncoprotein can be blocked by two monoclonal antibodies: trastuzumab (Herceptin) and pertuzumab (Omnitarg). The first one is able to bind to the IVth region of the extracellular domain of the protein and to trigger antibody-dependent cellular cytotoxicity (ADCC) by attracting the immune cells to the tumor site, while the second one recognizes the dimerization arm of ErbB2 protein being able to block the dimerization process [5, 7, 8, 38]. Pertuzumab in combination with trastuzumab and docetaxel had the approval of the U.S. Food and Drug Administration (FDA) for the treatment of metastatic breast cancer [60] and for the use as neoadjuvant therapy in case of the patients with HER-2 positive breast cancer [61]. Another type of molecules able to block the activity of ErbB proteins is tyrosine kinase inhibitors (TKI): gefitinib (Iressa), erlotinib (Tarceva), and lapatinib; the first two target the tyrosine kinase domain of EGFR with activating mutation (L747-S752 deletion) and are approved for clinical applications in NSCLC [6264]. A dual inhibitor of both EGFR and ErbB2 tyrosine kinases activity, lapatinib, had been applied mainly in metastatic breast cancer, since in other types of cancer it did not act as an effective inhibitor of the phosphorylation [65, 66].

The monoclonal antibodies and tyrosine kinase molecules showed improved response compared to nonspecific chemotherapy, but the positive responses have been limited to several months, being followed by diseases relapse. The causes of acquired resistance to synthesized molecules are various, for example, the acquisition of a new mutation in the molecular target (T790M EGFR) [67], masking the extracellular epitope of ErbB2 by hyaluronic acid [68], alternative pathways to support proliferation of the cancer cells (IGFR expression) [69], or loss of one of the negative regulators of PI3K/Akt survival pathway (phosphatase and tensin homolog, PTEN) [70].

Since the malignant transformation is not reduced to only one type of event, a complex approach which involves synergic activity of several compounds might bring effective results. The administration of pertuzumab, trastuzumab, and docetaxel to the patients with metastatic breast cancer positive for HER-2 improved progression-free survival [71]. Moreover, with the aim of reducing the tumor size before the surgery, the neoadjuvant chemotherapy was administrated to the patients in early stages of breast cancer positive for HER-2 [72]. Commonly, the adjuvant therapies are accompanied by severe side effects (nausea, vomiting, myelosuppression, cardiotoxicity, etc.) and by multidrug resistance [72]. In the last time, more attention has been paid to the combination between anticancer drugs and natural compounds as potential therapeutic approaches [73]. Some of the advantages of using the natural compounds are related to their pleiotropic effects and to the ability of being well tolerated by the human body [74]. However, most of the studies regarding the administration of natural compounds have been restricted to their preventive effects in cancer and clinical studies to support their therapeutic activity are missing [74, 75]. A summary of the natural molecules known to inhibit the activity of ErbB proteins is presented in Table 2.

NameTargetMechanism of actionClinical applications/
in vitro or in vivo experiments

Epigallocatechin-3-gallate (EGCG)EGFR
Inhibits the binding of EGF to EGFR followed by inhibition of the signaling pathways
Alters the lipid organization on the plasma membrane (lipid rafts)
Promotes internalization of nonactivated EGFR monomer
Reduces phosphorylation of EGFR
Clinical trial HNSCC;
in vitro experiments: epidermoid carcinoma cell line (A-431)
[84, 85, 166, 167]
Reduces the expression level of ErbB2 and ErbB3
Reduces phosphorylation of ErbB2 and ErbB3
In vitro experiments: prostate cancer cell lines[168, 169]
Induces degradation of ErbB2 by ubiquitination
Induces EGFR degradation
In vitro experiments: EGFR in several lung adenocarcinoma cell lines; ErbB2 transfected COS7 cell line[97, 98, 170]
ResveratrolErbB2Downregulates ErbB2 gene
Induces apoptosis
In vitro experiments: SK-BR-3 breast cancer cell lines[171]
Inhibits ErbB2 autophosphorylation and transphosphorylation
Depletes ErbB2 by polyubiquitination
Inhibits the activity of ErbB2/ErbB3 heterodimer
In vitro experiments: BT-474, SK-BR-3 breast cancer cell lines[172]

HNSCC, squamous cell carcinoma of the head and neck.

3. Biological Properties of Dietary Phytochemicals

Over the years dietary phytochemicals were proved to have numerous properties in chemoprevention of chronic diseases, including cancer [74]. For a better understanding about the beneficial properties of the dietary phytochemicals, many experiments, in vivo and in vitro, have been conducted. Dietary phytochemicals cover a large number of molecules and some were already shown to have biological activity in animal experiments and clinical trials. Their ability to interfere with abnormal proliferation of the cells, such as cancer progression, made them an attractive subject of study [74]. However, if natural compounds found in plants are not expected to treat cancer by themselves, a better understanding of their mechanisms of action can help us adopt the best strategy in cancer prevention or management. Phytochemicals have been classified according to their biological function, chemical structures, or the signaling pathway through which they act; regarding their chemical structure, phytochemicals are classified into polyphenols, alkaloids, carotenoids, and nitrogen compounds [76]. Polyphenols represent the substantial group of phytochemicals which showed many beneficial properties: antioxidant, anti-inflammatory, antitumor, neuroprotective, and antimicrobial [75, 77, 78].

Clinical studies have shown increasing incidence in metastatic cancer due to overexpression of ErbB2 protein [27]. Moreover, the overexpression of ErbB proteins, mutations, or amplification of their genes has been associated with cancer progression [7, 8]. Hence, potential dietary phytochemicals which downregulate ErbB proteins along with inhibiting the tyrosine kinase activity have been investigated.

3.1. EGCG

EGCG represents the most abundant polyphenolic catechin found in green tea [79]. Green tea, a popular beverage all over the world, possesses antioxidant properties, due, especially, to its high content in catechins. EGCG structure included eight hydroxyl groups and it was considered to possess anticarcinogenic effect due to its ability to induce apoptosis and to inhibit cell proliferation. The anticancer effect of EGCG was demonstrated through its ability to interfere with cell signaling pathways, NF-kB pathway, and cyclooxygenase-2 (COX-2) involved in cell transformation [80].

The anticarcinogenic properties of EGCG have been observed in multiple in vitro and in vivo studies. EGCG was proved to inhibit the tumor growth and the activation of ErbB1, ErbB2, and ErbB3 which are expressed in many different human cancer lines. Also, EGCG plays an important role in apoptosis and cell cycle arrest in tumor cells and in inhibiting the signaling pathways (MAPK, PI3K/AKT) and NF-kB activity [81]. Guo et al. demonstrated the effect of EGCG on NF639 cell line, which was obtained from a transgenic mouse, also called virus-HER-2/neu mouse. In this experiment EGCG inhibited the growth of mammary tumor cells in a dose-dependent manner; namely, 65% of the cells were inhibited by 40 μg/mL EGCG and 95% at 80 μg/mL EGCG. However, even after high doses of EGCG, 5% of colony formation showed resistance [82]. EGCG has been shown to have various anticancer effects in A431 epidermoid carcinoma cell line by blocking and inhibiting the tyrosine kinase activity of ErbB1 [83]. The activity of ErbB family members was decreased by EGCG in colon cancer cell lines, breast cancer, and human head and neck squamous cell carcinoma [81]. In the HT29 and SW80 colon cancer cell lines the treatments of EGCG also inhibited the ErbB2 and EGFR activity [84, 85]. Another two cell lines, BT-474 human breast cancer and YCU-H891 human head and neck squamous carcinoma cell lines, overexpressing ErbB2 were treated with EGCG to examine the inhibition of cell growth. After 72 h, EGCG showed a greater inhibition of tumor growth in YCU-H891 line than in BT-474 cells. Also, the effect of EGCG on ErbB2 phosphorylation in both cell lines was followed. The levels of phosphorylated ErbB2 (HER-2) were markedly decreased after 24 h at 10 μg/mL EGCG for YCU-H891 and 30 μg/mL EGCG for BT-474 [21]. In another study the inhibitory effect of EGCG on ErbB2 and ErbB3 overexpressing breast cancer cells was evaluated. Due to its ability to interfere with tyrosine-phosphorylation of ErbB2 and ErbB3, EGCG further inhibited downstream MAPK cascade, leading to the reduction in tumor growth [77]. In pancreatic cancer cells with ErbB protein expression [86] EGCG inhibited PI3K/Akt/mTOR pathway [87] and downregulated the activity of JAK/STAT3 pathway [88].

3.2. Curcumin

Curcumin (diferuloylmethane) is a nonflavonoid polyphenol found in turmeric derived from the roots of Curcuma longa plant. The yellow spice is widely used in Indian and in Ayurveda medicine as anti-inflammatory agent [89]. Besides curcumin, turmeric contains another three subclasses like demethoxycurcumin (curcumin II), bisdemethoxycurcumin (curcumin III), and cyclocurcumin [90]. Comparable to vitamin C, curcumin has been shown to be a better antioxidant [91]. Curcumin was first isolated from turmeric in 1815 but there was no report about its therapeutic properties until 1970s. Since then, curcumin has been increasingly studied for its promising effects. Besides its anti-inflammatory, anti-infectious, anticarcinogenic, and antioxidant properties, curcumin has been shown to interact with various extracellular and intracellular molecules involved in cancer progression having inhibitory effects on tumor cells [9294]. The antiproliferative effects of curcumin manifest through the regulation of growth factors, protein kinases, cell receptors, various oncogenic proteins, and the induction of apoptosis and cell cycle arrest in cancer cells [95].

The anticarcinogenic effects of curcumin were tested in both in vitro and in vivo studies. Experimental studies with curcumin were carried out in human breast cancer cell lines, which expressed , the oncoprotein encoded by gene. In vitro studies showed that autophosphorylation and transphosphorylation were inhibited by curcumin. Moreover, the depletion of with a curcumin IC50 (half maximal inhibitory concentration) of 6.5 μM for the 24 h treatment was detected [96]. In another study using SK-BR-3 human breast cancer cell line and COS7 monkey fibroblasts transiently transfected with ErbB2, curcumin downregulated ErbB2 protein by ubiquitination through chaperone-dependent ubiquitin ligase, carboxyl terminus of HSP70-interacting protein (CHIP) [97]. When the effect of curcumin on the human malignant testicular cell line NTera-2 was studied, the inhibition of ErbB2 expression and the reduced expression of activator protein-2 (AP) transcription factor were seen. Also in this study curcumin inhibited the tumor proliferation and induced apoptosis, through the inactivation of AP-2γ [98].

Beside the ability to inhibit the activity of EGFR, curcumin has been demonstrated to have pleiotropic biological effects which consist in the ability to modulate various signaling molecules like apoptotic proteins, proinflammatory transcription factors, such as NF-kB, cyclooxygenase-2, AP1, and signal transducer and activator of transcription (STAT) proteins [99, 100]. Additionally, in SK-BR-3 and BT-474 breast cancer cell lines with ErbB3 overexpression curcumin inhibited the phosphorylation of Akt and MAPK pathways [20]. A summary of the mechanisms of action in case of EGCG and curcumin in preclinical studies is illustrated in Figure 2.

Curcumin has also been studied in animal ErbB expressing or overexpressing cancer models where it was very well tolerated and showed promising effects such as tumor size reduction, apoptosis inducement, and tumor prevention [101103]. Some of those studies are summarized in Table 3.

Animal modelTreatmentMain resultsRef

EGFR overexpressing A431 epidermoid carcinoma xenograft in nude mice0.5 mg curcumin i.p. twice a day and 1 h visible light exposure after treatmentErbB1 phosphorylation reduction;
decreased tumor growth through proliferation reduction by 70% and 4-fold increased apoptosis
Erlotinib resistant ErbB1 mutant NSCLC xenograft in nude mice1 g/kg body weight curcumin, oral
10 mg/kg erlotinib
Curcumin reduced ErbB1 expression and induced apoptosis
Curcumin alone decreased tumor growth and increased erlotinib effect on tumor growth reduction
ErbB1 expressing LNCaP xenograft in nude mice2% curcumin in dietCurcumin decreased tumor volume, decreased mitosis, increased apoptosis, and inhibited tumor angiogenesis[103]
ErbB2 overexpressing BT-474 breast cancer xenograft in nude mice45 mg/kg curcumin i.p. twice per week for 4 consecutive weeksCurcumin reduced the expression level of ErbB2, p-Akt, p-MAPK, and NF-κB; curcumin decreased tumor volume by 76.7%[20]

4. Clinical Studies Involving EGCG and Curcumin

Both EGCG and curcumin were studied in a number of phase I and II clinical studies involving patients with developed cancers or at high risk of developing malignancies. Those studies focused on establishing the best treatment regime for further studies and due to the small number of patients employed do not provide much information on the treatment efficacy.

EGCG studies recommended doses of up to 800 mg oral EGCG daily. In those studies EGCG was administered in green tea catechins mixtures, as it was shown that such compositions potentiate the effect of the compound. EGCG was well tolerated in phase I and II clinical studies conducted with the most observed adverse effect being nausea found almost in all studies [104108]. The largest study conducted included 1075 postmenopausal women at risk of breast cancer randomized in treatment (843 ± 44 mg EGCG daily) and placebo groups and was designed to establish if the toxicity of EGCG was low enough to justify its use as a chemoprevention compound. Due to the fact that percentage of adverse effects in the treatment group did not significantly vary from the one in the placebo group and those adverse effects were mild, the study concludes that “green tea and concentrated catechin extracts have potential for use as a safe, natural supplement for breast cancer risk reduction in healthy populations” [108].

Phase I clinical studies recommended oral doses of about 4 g curcumin, daily [109, 110] or 8 g curcumin daily [111], doses that were well tolerated, with only low levels of toxicity reflected in serum enzyme increase [109] and mild hematological toxicity such as neutropenia [111113] and diarrhea [109, 110, 113]. In phase II clinical trials curcumin was also well tolerated when administered in combination with standard chemotherapeutic compounds such as docetaxel in advanced metastatic breast cancer [113] or gemcitabine in patients with advanced pancreatic cancer [112]. One study showed the colorectal cancer preventive action of curcumin, as the compound managed to reduce by 40% the number of aberrant crypt foci in high risk patients [110]. In summary, the main effects of EGCG and curcumin in clinical trials are presented in Table 4.

PhaseTreatmentSubjectsMain findingsAdverse effectsRef

II319.8 ± 47.9 mg EGCG oral daily from double brewed green tea16 women in complete remission after ovarian cancer5 women free of recurrence at 18 months
Not enough evidence to continue the study
Nausea, abdominal pain, vomiting; all adverse effects were of grade 1[104]
II1.3 g green tea polyphenols orally, daily, of which 800 mg EGCG was used until prostatectomy26 men with prostate cancerEGCG treatment reduced serum levels of HGF, VEGF, IGF-BP3, IGF-I, and PSANo adverse effects on liver function were observed[105]
II500, 750, and 1000 mg/m2 green tea extracts orally three times a day or placebo41 patients with oral premalignant lesionsHigher clinical response rate and histologic response rate in treatment group than in placebo
No statistical difference in oral cancer-free survival between the groups
Insomnia (due to caffeine contained in the formulation)
Ib200, 400, and 600 mg poly E extract (50–75% EGCG) or placebo44 patients with Barrett esophagus400 mg and 600 mg treatment resulted in organ accumulation of EGCG in esophageal mucosa
No significant changes in histological characteristics between cohorts
One placebo subject developed high-grade dysplasia
Abdominal pain/discomfort, diarrhea, loss of energy, nausea, upper respiratory infection, and ALT elevation[107]

I0.45 to 3.6 g oral curcumin daily, for 4 months15 patients with advanced colorectal cancer refractory to treatmentDose-limiting toxicity was not observed; stable disease after 2 months of treatment (2 patients); significant improvement in quality of life after 1 month of treatment (1 patient)Serum alkaline phosphatase rise, lactate dehydrogenase rise, mild to acute diarrhea associated with longer administration[109]
II8 g oral curcumin daily until disease progression25 patients with advanced pancreatic adenocarcinomaOne patient stable for > 18 months, another for 8 months, and one patient with a brief, 73% reduction in tumor sizeNo treatment related toxic effects observed[173]
II8 g oral curcumin daily + gemcitabine
1 g/m2 i.v. weekly × 3 of 4 wk
17 patients with advanced pancreatic cancerOut of the 11 evaluable patients, 9% had partial response, 36% had stable disease, and 55% had tumor progressionAbdominal fullness or pain
Mild hematological
I/II8 g oral curcumin daily,
1 g/m2 i.v. days 1 and 8, S-1 orally for 14 consecutive days every 3 weeks
21 patients with gemcitabine resistant pancreatic cancerOut of the 18 evaluable patients 28% showed stable diseaseHematological toxicity, fatigue (both probably associated with gemcitabine and not curcumin)[111]
I0.5 to 8 g oral curcumin daily + 75 to 100 mg/m2 docetaxel i.v. every 3 weeks14 patients with advanced and metastatic breast cancer5 patients with partial response to the treatment
3 patients with stable disease
Hematological toxicity (neutropenia and leucopenia)
IIa2 g or 4 g oral curcumin, daily for 30 days41 patients with >8 aberrant crypt foci, smokers4 g curcumin dose significantly reduced the number of premalignant lesions by 40%Toxicity (grade 1 to 3) or diarrhea[110]

5. Bioavailability

5.1. EGCG Bioavailability

While epidemiological studies showed positive effects of green and black tea consumption such as reduced ovarian [114], biliary tract [115], or hepatocellular carcinoma [116] cancer risk, researchers working with EGCG have been puzzled by the lack of overlapping between in vivo achievable EGCG concentrations and the EGCG concentrations proved efficient in in vitro studies. Thus, in the past years there has been an increasing interest in finding EGCG formulations to increase the bioavailability of the compound (Table 5).

SpeciesRouteDose Plasma/tissueAUCRef

Rati.v.10 mg/kgPlasma4.7 ± 0.9 μg/mL143.2 ± 32.1 min⋅μg/mL [117]
i.g.75 mg/kgPlasma19.8 ± 3.5 ng/mL17.4 ± 7.0 min⋅μg/mL
Rati.v.10 mg/kgPlasma12269.5 ± 2131.8 μg/L2772.2 ± 479.9 h⋅μg/L [118]
Oral100 mg/kgPlasma11.0 ± 5.9 μg/L39.6 ± 14.2 h⋅μg/L
Micei.v.21.8 μmol/kgPlasma13.6 ± 2.0 μmol/L38.4 ± 5.6 min⋅μmol/L [119]
Prostate0.31 ± 0.08 nmol/g56.1 ± 16.0 min⋅μmol/L
Lung2.66 ± 1.0 nmol/g91.0 ± 37.3 min⋅μmol/L
Spleen0.83 ± 0.22 nmol/g31.7 ± 9.2 min⋅μmol/L
Liver3.56 ± 0.8 nmol/g324.0 ± 79.5 min⋅μmol/L
Kidney2.12 ± 0.6 nmol/g55.0 ± 17.0 min⋅μmol/L
Small intestine2.40 ± 1.1 nmol/g114.0 ± 51.8 min⋅μmol/L
Colon1.20 ± 0.3 nmol/g325.3 ± 88.7 min⋅μmol/L
i.g.163.8 μmol/kgPlasma0.04 ± 0.01 μmol/L45.6 ± 13.5 min⋅μmol/L
HumanOral2 mg/kgPlasma34.71 _ 22.87 ng/mL213.7 ± 86.4 h⋅ng/mL [129]
HumanOral95 mgPlasmaNA857 h⋅ng/mL [131]
HumanOral200 mgPlasma73.7 ± 25.3 ng/mL22.5 ± 7.3 min⋅mg/mL [130]
Oral400 mgPlasma111.8 ± 98.6 ng/mL35.4 ± 21.5 min⋅mg/mL
Oral600 mgPlasma169.1 ± 139.6 ng/mL101.9 ± 99.7 min⋅mg/mL
Oral800 mgPlasma438.5 ± 284.4 ng/mL167.1 ± 57.0 min⋅mg/mL

i.v.: intravenous; i.g.: intragastric; , maximum concentration; AUC, area under the curve.

Absorption. EGCG absorption from decaffeinated green tea administered orally is only about 0.1%–0,15% in rats [117, 118] and about 12–26% in mice [119]. However, the EGCG absorption was shown to be modulated by the coadministration of EGCG with other dietary compounds such as piperine [120], sucrose and ascorbic acid [121], and genistein [122].

Area under the curve (AUC), an area of a concentration-time plot showing when the drug start to be administrated till its concentration in plasma is very low, was used to compare the effect of EGCG under different applications. When administered intragastrically in mice, 6 g/kg piperine increased AUC of total EGCG (coadministered at 75 g/kg) 1.2-fold and unconjugated EGCG 1.3-fold. The putative mechanism for this action was based on higher EGCG absorption through the inhibition of the intestinal glucuronidation of EGCG and, possibly, on gastrointestinal transit slowing [120]. The higher EGCG plasma bioavailability observed in sucrose and ascorbic acid formulation administered to rats may be caused by a longer gastric retention in the case of the higher viscosity formulation and a protective effect of ascorbic acid on EGCG oxidative degradation in the gastrointestinal tract [121].

Genistein was also found to increase EGCG bioavailability (about 1,5-fold increase in AUC) and plasma half-life; however 0.01% EGCG in drinking fluids and 0.2% genistein in food supplementation led to higher tumorigenesis in male adenomatous polyposis coli mice, limiting the use in vivo of such combinations [122]. EGCG was also shown to modulate its own bioavailability. When low doses, similar to those in green tea, were administered, a second dose of EGCG at 6 hours increases the EGCG available in blood and organs 4–6-fold [123]. On the other hand, AUC was 1.3-fold lower in pretreated mice (3.2 mg/g EGCG for two weeks before the main dose) compared to nontreated mice which receive only the main dose (750 mg/kg EGCG) [124], showing a different modulation mechanism for higher EGCG doses after different term exposure to this flavonoid.

Metabolism. The EGCG low bioavailability is also regulated by multidrug resistance proteins (MRP) and high catechol-O-methyltransferase (COMT) methylation [125] ratios that lead to less active forms [118] like 4′′-O-methyl EGCG, the main methylation product [126, 127]. Also, after absorption, EGCG shows pronounced plasma glucuronidation but, if administered intravenously (i.v.), most of EGCG found in tissues is unconjugated [119]. Glucuronidation occurs in a lesser extent in intestine and liver microsomes, about 12% in 3 h [128].

Distribution. A study using [3H]-labeled EGCG showed wide distribution of the catechin in mouse tissues over a period of 24 hours after EGCG administration for one time, with concentrations in the liver, lung, pancreas, ovary, and mammary gland in the same order of magnitude as those found in plasma; the concentrations in the gastrointestinal tract were the highest, one or two orders of magnitude higher than those found in plasma, depending on the time-point analyzed [123].

Elimination. EGCG elimination occurs mainly through bile, as shown by a 4-fold or 2-fold higher AUC in the intestine compared to the kidney if decaffeinated green tea extract was administrated i.v. in rats [117] or mice, respectively [119].

In humans, EGCG reaches maximum plasma concentration after 1.3–1.6 hours at lower doses [129] and can reach up to 4 hours for doses of 800 mg [130]. EGCG has an elimination half-life of about 3.4 hours, being cleared completely from plasma after 24 hours [129, 130]. Similar to what was shown in animal studies, in healthy human subjects, EGCG bioavailability can be increased by other phytochemical compounds. EGCG formulated with low caffeine concentrations (EGCG to CAF ratio of 2 : 4) presented an AUC in blood 50% higher than EGCG alone, but higher caffeine concentrations failed to prove the same effect [131].

In conclusion, the bioavailability of EGCG may be moderately increased by other different phytochemicals and by a proper dosing regimen.

5.2. Curcumin Bioavailability

Curcumin can be safely administered to humans in doses up to 12 g [132] and one dose escalation study recommended a dose of 6 g curcumin daily for one week, every three weeks [113]. Yet even when a 12 g dose was administered, curcumin serum levels only reached a maximum less of than 60 ng/mL at the 2-hour time-point [132].

Absorption. The main reason for the low bioavailability of curcumin is its insufficient water solubility, causing low absorption rates. Thus, a nanoparticle formulation strategy using particles formed from either low molecular weight (5–15 kD) or high molecular weight (50–75 kD) polylactic-co-glycolic acid found no differences between the two polymer sizes but a bioavailability 40 times greater than for free curcumin administration in rats [133].

Another method of increasing curcumin water solubility, and therefore its bioavailability, is complexing curcumin with phosphatidylcholine (PC). Thus, curcumin-PC complexes reach more than triple plasma concentrations and higher AUC at same concentrations than curcumin when it was administered in rats [134]. Other conjugation strategies have also been employed for increasing curcumin stability and solubility in water, such as combining it with hyaluronic acid [135], polyethylene glycol [136], or dendrimers [137], but have not been tested in vivo yet.

Curcumin water solubility was also increased successfully using a microemulsion vehicle containing a surfactant, oil, and cosurfactant and this increase in water solubility translated in an about 22 times higher bioavailability of curcumin in rats [138]. A 13-fold increase in bioavailability was observed also in the case of curcumin formulated as amorphous solid dispersion in a matrix consisting of hydroxypropyl methyl cellulose (HPMC), lecithin, and isomalt [139].

A new strategy to overcome curcumin bioavailability problems is the production of novel curcumin analogs. Such curcumin analogs developed for better water solubility can reach bioavailabilities of up to 60% when orally administered in mice [140]. Some curcumin analogs show improved anticancer effects in silico and in vitro [141], while others have already been tested in vivo and showed improvement in colorectal cancer [142] and glioma [143] survival or inhibited gastric carcinogenesis in mice. Such strategy may prove to find analogs not only with higher bioavailability, but also with improved biological activity. Different strategies for improving bioavailability can be the nanoformulated curcumin analogs which aim at a more specific distribution in tumor tissue [144].

Metabolism. Curcumin is conjugated in liver and intestine microsome to curcumin glucuronide and curcumin sulfate; hepatic and intestinal alcohol dehydrogenase reduces curcumin to hexahydrocurcumin [145]. There are differences in rat and human curcumin metabolisation, as intestinal microsomes produced 16 times greater curcumin glucuronide in humans than in rats, but hepatic glucuronidation was 3 times higher in rats [145], imposing a certain degree of caution when extrapolating bioavailability results obtained in rats to humans.

Curcumin bioavailability is further hindered by autoxidation processes at physiologic pH. Thus curcumin oxidation forms a large number of intermediary metabolites such as quinone methide, peroxyl radical, endoperoxide, spiroepoxide, vinylether, and cyclopentadione [146] leading to the formation of bicyclopentadione [147].

Distribution. Curcumin and curcumin nanoparticles have different tissue distributions when administered intravenously. Curcumin nanoparticles present higher bioavailability than curcumin in liver, spleen, and lung than curcumin, while distribution to the heart, kidney, and brain is not greatly affected by nanoformulation, although slightly increased in brain and kidney [133].

Elimination. Though not entirely demonstrated, it has been theorized that curcumin conjugates are eliminated mainly through renal clearance [148] although curcumin conjugates were also found in feces [149].

In humans, nanoparticle curcumin formulations have already been tested on healthy volunteers and it was shown that they can reach plasma concentrations four times higher at the same time-point when administered in much lower doses of about 200 mg [150] and show 27-fold higher bioavailability than curcumin powder [151]. Also, similar to EGCG, piperine was also found to increase curcumin bioavailability in humans through the inhibition of curcumin glucuronidation which might prove useful in curcumin-EGCG coadministration formulations [152, 153]. Table 6 shows the bioavailability of curcumin in humans and in animal models.


Rati.v.25 mg/kgLiverNA9.06 ± 1.55 min⋅g/mL [133]
HeartNA3.03 ± 0.85 min⋅g/mL
SpleenNA5.72 ± 1.14 min⋅g/mL
LungNA8.98 ± 1.82 min⋅g/mL
KidneyNA12.0 ± 0.88 min⋅g/mL
BrainNA4.04 ± 0.22 min⋅g/mL
RatOral50 mg/kgPlasma13.0 ± 5.8 ng/mL51.1 ± 25 min⋅g/mL [151]
300 mg/kgPlasma37.4 ± 36.1 ng/mL134 ± 114 min⋅g/mL
RatOral1 g/kgPlasma258.64 ng/mL2483.32 h⋅ng/mL [134]
HumanOral30 mg/kgPlasma1.8 ± 2.8 ng/mL4.1 ± 7 h⋅ng/mL [151]
HumanOral10 gPlasma50.5 ng/mLNA [132]
12 gPlasma57.6 ng/mLNA

i.v.: intravenous; i.g.: intragastric; , maximum concentration; AUC, area under the curve; NA, not applicable.

To conclude, even if orally administrated curcumin shows a very little bioavailability, the bioavailability of the compound can be greatly increased using formulations that compensate for the low water solubility of the product and by using curcumin analogs with not only higher solubility but also higher stability.

6. Synergistic Activity of EGCG and Curcumin

Because of natural compounds low bioavailability, there is a need to find synergistic associations that might produce anticancer effects even at lower compound concentrations. Several possible combinations between EGCG or curcumin and anticancer drugs had been proven to potentiate the effects of the anticancer drugs in in vitro or in vivo studies [154157]. At the same time the combination of EGCG or curcumin with other natural compounds brought additional information about the ability of natural compounds to decrease cell growth, to induce apoptosis or induce cell cycle arrest [158160]. However a considerable lack of data was noticed regarding the clinical studies concerning the patients with ErbB positive tumors. Additionally, the lack of direct studies regarding ErbB proteins and synergistic activity of EGCG and curcumin was overcome by summarizing in Table 7 the malignant cell lines used for in vitro or in vivo experiments introduced in this chapter, according to the tissue origin of the cell line and the expression of ErbB proteins.

Cell lineTissue/organErbB proteinsReference

A2780Ovarian cancer cell lineEGFR: negative, ErbB2: positive, ErbB3: low positive, ErbB4: positive[174]
Tu212Hypopharyngeal cancer cell lineEGFR: positive[158]
A549Human lung carcinoma cell lineEGFR: positive[158]
MDA-MB-231Human breast cancer cell lineEGFR: positive, ErbB2: negative/positive[175]
MCF-7Human breast cancer cell lineEGFR, ErbB2: positive[175]
DLD-1Human colon cancer cell lineEGFR, ErbB2: positive[176]
HT-29Human colon cancer cell lineEGFR, ErbB2: positive[176]
HCT 116Human colon cancer cell lineEGFR, ErbB2: positive[176]
TE-8Human esophageal cancer cell lineEGFR: positive[177]
SKGT-4Human esophageal cancer cell lineEGFR: positive[178]
HepG2Human hepatocarcinoma cell lineEGFR, ErbB2: positive[179, 180]
CWR22RProstate cancer cell lineEGFR, ErbB2: positive[181]
Y79Human retinoblastoma cell lineErbB2: positive[182]

6.1. Synergistic Activity between Natural Compounds and Anticancer Drugs

EGCG was shown to synergistically interact with other drugs employed in cancer treatment and reduced cell viability, increased apoptosis, or inhibited cell growth had been observed [154156]. Resistance to chemotherapy is an important factor of negative prognostic in oncology patients and therefore the synergy of the natural compounds may prove to play an important role in the treatment of chemoresistant tumors as they were shown to be effective in cisplatin resistant ovarian cancer cells [154, 155]. There are data suggesting a better potentiation of the activity of the compound by sequential administration. In ovarian cancer cells, the effect of cisplatin or oxaliplatin was synergistically increased by curcumin or EGCG administration only when the natural compound was administered after cisplatin at 4 hours, but not before [154, 155]. Curcumin analogs appear to maintain cisplatin potentiating effect, as proved on a cisplatin resistant carcinoma xenograft model [157]. Table 8 summarizes the synergistic activity of EGCG or curcumin and anticancer drugs both in in vitro and in vivo experiments in ErbB positive cells lines or xenograft tumors.

Anticancer drugBiological system/modelDosesMain resultsRef

EGCG: in vitro experiments
Oxaliplatin, cisplatinA2780 and A2780R ovarian cancer cell lines parental and cisplatin resistant, respectivelyED50, ED75, ED90 (ED, effective dose)Increased synergism at ED50 after the sequential administration of the phytochemical, at 4 h after oxaliplatin or cisplatin treatment (increased growth inhibitory effects)[154, 155]
Oxaliplatin, cisplatinDLD-1, HT-29 human colorectal adenocarcinoma cells100 μM EGCG
20 μM oxaliplatin or cisplatin
Decreased cell proliferation, induced autophagy[156]

Curcumin: in vitro experiments
Carboplatin, etoposide, vincristineY 79 retinoblastoma cells5–10 μM curcumin
5–10 μg/mL carboplatin
0.1–5 μg/mL etoposide
0.1–5 nM vincristine
Increased apoptosis
Curcumin increased the sensitivity of retinoblastoma cells to carboplatin, etoposide, and vincristine
OxaliplatinA2780 and A2780R ovarian cancer cell lines parental and cisplatin resistant, respectivelyED50, ED75, ED90 (ED, effective dose)Increased synergism at ED50 after the sequential administration of the phytochemical, at 4 h after oxaliplatin (increased growth inhibitory effects)[154, 155]
CisplatinA2780R cisplatin resistant human ovarian cancer cell line1–10 μM curcumin analogs
10 μg/mL cisplatin
Cotreatment increased cytotoxicity (MTT assay), induced G2/M arrest, increased p21 and p53 levels, decreased Bcl-2 and Bcl-XL levels, increased caspase-9, caspase-3, and caspase-7 and PARP levels, increased apoptosis, and reduced STAT3 level[157]

Curcumin: in vivo experiments
CisplatinXenograft tumor in nude mice with A2780R cells Cisplatin resistant ovarian cancer cells100 ppm curcumin analogs in feed
4 mg/kg cisplatin i.p.
Cotreatment reduced the tumor volume, decreased constitutive activation of pSTAT3-Tyr705 and pSTAT3-Ser727, decreased Bcl-2 and Bcl-XL levels, and increased PARP levels[157]

6.2. Synergistic Activity between Natural Compounds

In EGFR+ esophageal cancer lines curcumin and EGCG also greatly reduced p-Erk1/2 expression and increase caspase-3 level [161]. The combination between EGCG and curcumin administrated to breast cancer stem cell model reduced the number of CD44 positive cells and reduced the tumor-sphere formation reversing the stem cell phenotype [162]. In vitro studies found synergistic effects for either curcumin or EGCG when administered together with other dietary compounds. EGCG was found to exert synergistic apoptosis inducing effects with compounds such as resveratrol or gamma-tocotrienol in breast cancer cells [159], genistein and quercetin in prostate cancer cells [160], or luteolin in several head and neck cancer cell lines or lung cancer cells [158]. Curcumin was also shown to be potentiated by resveratrol in hepatocellular carcinoma cells [163]. In a xenograft model of non-small-cell lung cancer, 20 mg/kg curcumin and 100 mg/kg EGCG coadministration also reduced tumor size through cyclin D1 and cyclin B1 inhibition which led to cell cycle arrest in G2/M phase in [161]. The coadministration EGCG and curcumin significantly reduced tumor size in several xenograft nude mouse models [161, 164, 165]. However, little in vivo findings support the clinical use of such combinations yet. The synergy studies between EGCG and curcumin or EGCG/curcumin and other natural compounds have been summarized in Table 9.

Natural compoundBiological system/modelDosesMain resultsRef

EGCG: in vitro experiments
CurcuminTE-8 and SKGT-7 esophageal cancer cell lines20–40 μM EGCG
20–40 μM curcumin
Reduced viability and invasion ability, reduced pErk1/2 and COX-2, increased caspase-3 level[161]
MDA-MB-231 breast cancer cell line25 μM EGCG
3 μM curcumin
Increased synergistically the cytotoxicity correlated with G2/M phase arrest[164]
MDA-MB-231 and MCF-7 breast cancer cell lines transfected with ErbB2 to mimic breast cancer stem cells10 μM EGCG
10 μM curcumin
Cotreatment reduced the number of CD44 positive cells, reduced the tumor-sphere formation, and reduced the level of pSTAT3[162]
MCF-7 breast cancer cell line50 μM EGCG
25 μM resveratrol
10 μM γ-tocotrienol
Inhibited cell proliferation
Additive effect when EGCG was combined with γ-tocotrienol in reducing the levels of cyclin D1 and Bcl-2
Increased level of antioxidant enzyme NQO1 when all three phytochemicals were used
Genistein, quercetinCWR22Rv1 prostate cancer cells2.5 μM EGCG
2.5 μM genistein
2.5 μM quercetin
Coadministration of EGCG with genistein or quercetin reduced the cell proliferation and increased cell death compared to each treatment alone (the effects were more pronounced in case of combination of EGCG with quercetin)[160]
LuteolinSeveral human head and neck cancer cells from the primary tumor and their lymph node metastasis (Tu212, Tu686, 686LN, and 886LN) and several lung cancer cell lines (H292, A549, H460, H358, H322, H1299, and Calu-1)30 μM EGCG
10 μM luteolin
Synergistically increased the level of apoptosis (3–5-fold) compared to the additive level
Mitochondrial translocation of p53 after the combined treatment

Curcumin: in vitro experiments
ResveratrolHepa 1–6 murine hepatocarcinoma cell line2.5–40 μM curcumin
10–160 μM luteolin (fixed ratio 1 : 4)
Synergistic effect of the cotreatment consisted in reduced cell survival. The following apoptosis effects were observed: increased annexin V-propidium iodide positive staining, increased caspase-3 activity, increased the number of the nuclei with apoptotic morphology, increased ROS production[163]
SilymarinDLD-1, LoVo, HCT116 human colon cancer cells0–100 μM curcumin
0–100 μM silymarin
Cotreatment induced: increased antiproliferative effects, increased apoptosis, reduced cell survival[184]

EGCG: in vivo experiments
CurcuminXenograft nude mouse model with SKGT-4 esophageal cancer cells50 μg/kg EGCG
50 μg/kg curcumin
Reduced tumor size after cotreatment
Reduced expression of Ki67, pERK, and cyclooxygenase-2 in immunohistochemistry
Xenograft nude mouse model with A549
non-small-cell lung cancer cells (females)
100 mg/kg EGCG
20 mg/kg curcumin
Cotreatment protected the mice against weight loss, reduced the tumor growth, reduced cyclin D1 and B2, and reduced the level of the proliferation marker Ki-67[165]
Xenograft nude mouse model with MDA-MB-231 breast cancer cells (females)25 mg/kg EGCG
25 mg/kg curcumin
Cotreatment decreased the tumor volume (by 49%) and the protein expression level of VEGFR-1 (by 78%), but not the levels of EGFR and Akt[164]
LuteolinXenograft nude mice with Tu212 hypopharyngeal cancer cell line125 mg/kg EGCG
10 mg/kg luteolin
Synergistically decreased in Ki-67 expression and increased in TUNEL positive cells and inhibition of tumor volume[158]

A new mechanism described for both EGCG and curcumin which might explain in part the synergistic effects of the two compounds when administered together or with other therapeutic compounds is the modulation of multiple miRNA expression [185, 186]. miRNA are small RNA fragments produced by noncoding DNA that have been found to play roles in many cancer-associated mechanisms such as cell differentiation, cell cycle, drug resistance, and metastasis [187]. EGCG was shown to decrease expression of oncogenic miR92, miR93, and miR106 while increasing tumor suppressors miR-7-1, miR-34a, and miR-99a in neuroblastoma cancer cells and curcumin was shown to increase expression of tumor suppressors miR-22, miR-34a, miR-101, miR-141, miR429, miR-200b, miR-200c while downregulating miR199a, in colorectal cancer cells or pancreatic cancer cells [188, 189].

7. Conclusions

Up to date the dietary phytochemicals have been used as chemopreventive agents or as potential therapeutic molecules in cancer models and their efficacy as therapeutic agents is missing, suggesting that the most promising results from in vitro or in vivo experiment might represent a start point for the future approaches in clinical studies. Moreover, the reduced bioavailability of the phytochemicals may represent future challenges for those working in the field. Better understanding of the molecular mechanisms about dietary phytochemicals in translational studies, from in vitro to clinical trials, will help us to identify future potential agents or combination of them for the chemoprevention of cancer.

Competing Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contributions

Alexandru Filippi and Oana-Alina Ciolac contributed equally to this work. All authors read and approved the final version of the manuscript.


This work was supported by the Romanian Ministry of Education and by the visiting professors fellowship program conducted by the Research Institute of the University of Bucharest.


  1. C. L. Arteaga and J. A. Engelman, “ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics,” Cancer Cell, vol. 25, no. 3, pp. 282–303, 2014. View at: Publisher Site | Google Scholar
  2. H. Wu, Z. Cai, G. Lu et al., “Impact of c-erbB-2 protein on 5-year survival rate of gastric cancer patients after surgery: a cohort study and meta-analysis,” Tumori Journal, 2015. View at: Publisher Site | Google Scholar
  3. S. Dębska-Szmich, R. Kusińska, U. Czernek et al., “Prognostic value of HER3, PTEN and p-HER2 expression in patients with HER2positive breast cancer,” Postępy Higieny i Medycyny Doświadczalnej, vol. 69, pp. 586–597, 2015. View at: Publisher Site | Google Scholar
  4. A. Appert-Collin, P. Hubert, G. Crémel, and A. Bennasroune, “Role of ErbB receptors in cancer cell migration and invasion,” Frontiers in Pharmacology, vol. 6, article 283, 2015. View at: Publisher Site | Google Scholar
  5. Y. Yarden and M. X. Sliwkowski, “Untangling the ErbB signalling network,” Nature Reviews Molecular Cell Biology, vol. 2, no. 2, pp. 127–137, 2001. View at: Publisher Site | Google Scholar
  6. D. J. Arndt-Jovin, M. G. Botelho, and T. M. Jovin, “Structure-function relationships of ErbB RTKs in the plasma membrane of living cells,” Cold Spring Harbor Perspectives in Biology, vol. 6, no. 4, Article ID a008961, 2014. View at: Publisher Site | Google Scholar
  7. R. Roskoski, “The ErbB/HER family of protein-tyrosine kinases and cancer,” Pharmacological Research, vol. 79, pp. 34–74, 2014. View at: Publisher Site | Google Scholar
  8. N. E. Hynes and H. A. Lane, “ERBB receptors and cancer: the complexity of targeted inhibitors,” Nature Reviews Cancer, vol. 5, no. 5, pp. 341–354, 2005. View at: Publisher Site | Google Scholar
  9. R. I. C. Russo, W. Béguelin, M. C. Díaz Flaqué et al., “Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance,” Oncogene, vol. 34, no. 26, pp. 3413–3428, 2015. View at: Publisher Site | Google Scholar
  10. B. F. Adem, N. R. A. Bastos, F. Dias, A. L. Teixeira, and R. Medeiros, “MiRNAs: mediators of ERBB family targeted therapy resistance,” Pharmacogenomics, vol. 17, no. 10, pp. 1175–1187, 2016. View at: Publisher Site | Google Scholar
  11. R. Nahta, D. Yu, M.-C. Hung, G. N. Hortobagyi, and F. J. Esteva, “Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer,” Nature Clinical Practice Oncology, vol. 3, no. 5, pp. 269–280, 2006. View at: Publisher Site | Google Scholar
  12. Y. He, Y. Yue, X. Zheng, K. Zhang, S. Chen, and Z. Du, “Curcumin, inflammation, and chronic diseases: how are they linked?” Molecules, vol. 20, no. 5, pp. 9183–9213, 2015. View at: Publisher Site | Google Scholar
  13. M. K. Shanmugam, G. Rane, M. M. Kanchi et al., “The multifaceted role of curcumin in cancer prevention and treatment,” Molecules, vol. 20, no. 2, pp. 2728–2769, 2015. View at: Publisher Site | Google Scholar
  14. S. Prasad and A. K. Tyagi, “Curcumin and its analogues: a potential natural compound against HIV infection and AIDS,” Food and Function, vol. 6, no. 11, pp. 3412–3419, 2015. View at: Publisher Site | Google Scholar
  15. H. Tachibana, “Green tea polyphenol sensing,” Proceedings of the Japan Academy, Series B, vol. 87, no. 3, pp. 66–80, 2011. View at: Publisher Site | Google Scholar
  16. P.-L. Liu, J.-T. Liu, H.-F. Kuo, I.-W. Chong, and C.-C. Hsieh, “Epigallocatechin gallate attenuates proliferation and oxidative stress in human vascular smooth muscle cells induced by interleukin-1β via heme oxygenase-1,” Mediators of Inflammation, vol. 2014, Article ID 523684, 8 pages, 2014. View at: Publisher Site | Google Scholar
  17. F. Wu, H. Sun, T. Kluz, H. A. Clancy, K. Kiok, and M. Costa, “Epigallocatechin-3-gallate (EGCG) protects against chromate-induced toxicity in vitro,” Toxicology and Applied Pharmacology, vol. 258, no. 2, pp. 166–175, 2012. View at: Publisher Site | Google Scholar
  18. J. Steinmann, J. Buer, T. Pietschmann, and E. Steinmann, “Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea,” British Journal of Pharmacology, vol. 168, no. 5, pp. 1059–1073, 2013. View at: Publisher Site | Google Scholar
  19. D. Chen, S. B. Wan, H. Yang, J. Yuan, T. H. Chan, and Q. P. Dou, “EGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment,” Advances in Clinical Chemistry, vol. 53, pp. 155–177, 2011. View at: Publisher Site | Google Scholar
  20. H.-W. Lai, S.-Y. Chien, S.-J. Kuo et al., “The potential utility of curcumin in the treatment of HER-2-overexpressed breast cancer: an in vitro and in vivo comparison study with herceptin,” Evidence-based Complementary and Alternative Medicine, vol. 2012, Article ID 486568, 12 pages, 2012. View at: Publisher Site | Google Scholar
  21. M. Masuda, M. Suzui, J. T. E. Lim, and I. B. Weinstein, “Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells,” Clinical Cancer Research, vol. 9, no. 9, pp. 3486–3491, 2003. View at: Google Scholar
  22. M. Bassiri and M. L. Privalsky, “Mutagenesis of the avian erythroblastosis virus erbB coding region: an intact extracellular domain is not required for oncogenic transformation,” Journal of Virology, vol. 59, no. 2, pp. 525–530, 1986. View at: Google Scholar
  23. K. Khazaie, T. J. Dull, T. Graf et al., “Truncation of the human EGF receptor leads to differential transforming potentials in primary avian fibroblasts and erythroblasts,” EMBO Journal, vol. 7, no. 10, pp. 3061–3071, 1988. View at: Google Scholar
  24. S. Sundaresan, E. Penuel, and M. X. Sliwkowski, “The biology of human epidermal growth factor receptor 2,” Current Oncology Reports, vol. 1, no. 1, pp. 16–22, 1999. View at: Publisher Site | Google Scholar
  25. A. L. Schechter, D. F. Stern, L. Vaidyanathan et al., “The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen,” Nature, vol. 312, no. 5994, pp. 513–516, 1984. View at: Publisher Site | Google Scholar
  26. C. Shih, L. C. Padhy, M. Murray, and R. A. Weinberg, “Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts,” Nature, vol. 290, no. 5803, pp. 261–264, 1981. View at: Publisher Site | Google Scholar
  27. D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire, “Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene,” Science, vol. 235, no. 4785, pp. 177–182, 1987. View at: Publisher Site | Google Scholar
  28. D. J. Slamon, W. Godolphin, L. A. Jones et al., “Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer,” Science, vol. 244, no. 4905, pp. 707–712, 1989. View at: Publisher Site | Google Scholar
  29. M. J. Van de Vijver, J. L. Peterse, W. J. Mooi et al., “Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in Stage II breast cancer,” New England Journal of Medicine, vol. 319, no. 19, pp. 1239–1245, 1988. View at: Publisher Site | Google Scholar
  30. A. L. Hughes, J. da Silva, and R. Friedman, “Ancient genome duplications did not structure the human Hox-bearing chromosomes,” Genome Research, vol. 11, no. 5, pp. 771–780, 2001. View at: Publisher Site | Google Scholar
  31. P. J. Miettinen, J. E. Berger, J. Meneses et al., “Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor,” Nature, vol. 376, no. 6538, pp. 337–341, 1995. View at: Publisher Site | Google Scholar
  32. M. Sibilia and E. F. Wagner, “Strain-dependent epithelial defects in mice lacking the EGF receptor,” Science, vol. 269, no. 5221, pp. 234–238, 1995. View at: Publisher Site | Google Scholar
  33. D. W. Threadgill, A. A. Dlugosz, L. A. Hansen et al., “Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype,” Science, vol. 269, no. 5221, pp. 230–234, 1995. View at: Publisher Site | Google Scholar
  34. A. R. Tan, X. Yang, S. M. Hewitt et al., “Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor,” Journal of Clinical Oncology, vol. 22, no. 15, pp. 3080–3090, 2004. View at: Publisher Site | Google Scholar
  35. K.-F. Lee, H. Simon, H. Chen, B. Bates, M.-C. Hung, and C. Hauser, “Requirement for neuregulin receptor erbB2 in neural and cardiac development,” Nature, vol. 378, no. 6555, pp. 394–398, 1995. View at: Publisher Site | Google Scholar
  36. S. A. Crone, Y.-Y. Zhao, L. Fan et al., “ErbB2 is essential in the prevention of dilated cardiomyopathy,” Nature Medicine, vol. 8, no. 5, pp. 459–465, 2002. View at: Publisher Site | Google Scholar
  37. I. B. Fuchs, S. Landt, H. Bueler et al., “Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin™),” Breast Cancer Research and Treatment, vol. 82, no. 1, pp. 23–28, 2003. View at: Publisher Site | Google Scholar
  38. Y. Yarden and G. Pines, “The ERBB network: at last, cancer therapy meets systems biology,” Nature Reviews: Cancer, vol. 12, no. 8, pp. 553–563, 2012. View at: Publisher Site | Google Scholar
  39. A. W. Burgess, H.-S. Cho, C. Eigenbrot et al., “An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors,” Molecular Cell, vol. 12, no. 3, pp. 541–552, 2003. View at: Publisher Site | Google Scholar
  40. H.-S. Cho and D. J. Leahy, “Structure of the extracellular region of HER3 reveals an interdomain tether,” Science, vol. 297, no. 5585, pp. 1330–1333, 2002. View at: Publisher Site | Google Scholar
  41. T. P. J. Garrett, N. M. McKern, M. Lou et al., “The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors,” Molecular Cell, vol. 11, no. 2, pp. 495–505, 2003. View at: Publisher Site | Google Scholar
  42. H.-S. Cho, K. Mason, K. X. Ramyar et al., “Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab,” Nature, vol. 421, no. 6924, pp. 756–760, 2003. View at: Publisher Site | Google Scholar
  43. P. Nagy, A. Jenei, S. Damjanovich, T. M. Jovin, and J. SzÖllÔsi, “Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy,” Pathology and Oncology Research, vol. 5, no. 4, pp. 255–271, 1999. View at: Publisher Site | Google Scholar
  44. C. P. Blobel, “ADAMs: key components in egfr signalling and development,” Nature Reviews: Molecular Cell Biology, vol. 6, no. 1, pp. 32–43, 2005. View at: Publisher Site | Google Scholar
  45. N. Rocks, G. Paulissen, M. El Hour et al., “Emerging roles of ADAM and ADAMTS metalloproteinases in cancer,” Biochimie, vol. 90, no. 2, pp. 369–379, 2008. View at: Publisher Site | Google Scholar
  46. L. Yen, N. Benlimame, Z.-R. Nie et al., “Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers,” Molecular Biology of the Cell, vol. 13, no. 11, pp. 4029–4044, 2002. View at: Publisher Site | Google Scholar
  47. Q. Jin and F. J. Esteva, “Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer,” Journal of Mammary Gland Biology and Neoplasia, vol. 13, no. 4, pp. 485–498, 2008. View at: Publisher Site | Google Scholar
  48. L. Pentassuglia and D. B. Sawyer, “ErbB/integrin signaling interactions in regulation of myocardial cell-cell and cell-matrix interactions,” Biochimica et Biophysica Acta—Molecular Cell Research, vol. 1833, no. 4, pp. 909–916, 2013. View at: Publisher Site | Google Scholar
  49. R. Schiff, S. A. Massarweh, J. Shou et al., “Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance,” Clinical Cancer Research, vol. 10, no. 1, part 2, pp. 331S–336S, 2004. View at: Publisher Site | Google Scholar
  50. A. Prat and J. Baselga, “The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2,” Nature Clinical Practice Oncology, vol. 5, no. 9, pp. 531–542, 2008. View at: Publisher Site | Google Scholar
  51. S. Cohen, R. A. Fava, and S. T. Sawyer, “Purification and characterization of epidermal growth factor receptor/protein kinase from normal mouse liver,” Proceedings of the National Academy of Sciences of the United States of America, vol. 79, no. 20, pp. 6237–6241, 1982. View at: Publisher Site | Google Scholar
  52. M.-M. Mocanu, Z. Fazekas, M. Petrás et al., “Associations of ErbB2, β1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines,” Cancer Letters, vol. 227, no. 2, pp. 201–212, 2005. View at: Publisher Site | Google Scholar
  53. R. S. Herbst, J. V. Heymach, and S. M. Lippman, “Lung cancer,” The New England Journal of Medicine, vol. 359, no. 13, pp. 1367–1380, 2008. View at: Publisher Site | Google Scholar
  54. M. A. Owens, B. C. Horten, and M. M. Da Silva, “HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues,” Clinical Breast Cancer, vol. 5, no. 1, pp. 63–69, 2004. View at: Publisher Site | Google Scholar
  55. J. Lee and S.-H. I. Ou, “Towards the goal of personalized medicine in gastric cancer—time to move beyond HER2 inhibition. Part I: targeting receptor tyrosine kinase gene amplification,” Discovery Medicine, vol. 15, no. 85, pp. 333–341, 2013. View at: Google Scholar
  56. J. P. Spano, R. Fagard, J.-C. Soria, O. Rixe, D. Khayat, and G. Milano, “Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives,” Annals of Oncology, vol. 16, no. 2, pp. 189–194, 2005. View at: Publisher Site | Google Scholar
  57. E. Aboud-pirak, E. Hurwitz, M. E. Pirak, F. Bellot, J. Schlessinger, and M. Sela, “Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice,” Journal of the National Cancer Institute, vol. 80, no. 20, pp. 1605–1611, 1988. View at: Publisher Site | Google Scholar
  58. C. Kollmannsberger, M. Schittenhelm, F. Honecker et al., “A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC),” Annals of Oncology, vol. 17, no. 6, pp. 1007–1013, 2006. View at: Publisher Site | Google Scholar
  59. W. A. Messersmith and M. Hidalgo, “Panitumumab, a monoclonal anti-epidermal growth factor receptor antibody in colorectal cancer: another one or the one?” Clinical Cancer Research, vol. 13, no. 16, pp. 4664–4666, 2007. View at: Publisher Site | Google Scholar
  60. G. M. Blumenthal, N. S. Scher, P. Cortazar et al., “First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer,” Clinical Cancer Research, vol. 19, no. 18, pp. 4911–4916, 2013. View at: Publisher Site | Google Scholar
  61. L. Amiri-Kordestani, G. M. Blumenthal, Q. C. Xu et al., “FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer,” Clinical Cancer Research, vol. 20, no. 17, pp. 4436–4441, 2014. View at: Publisher Site | Google Scholar
  62. T. J. Lynch, D. W. Bell, R. Sordella et al., “Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib,” New England Journal of Medicine, vol. 350, no. 21, pp. 2129–2139, 2004. View at: Publisher Site | Google Scholar
  63. R. Rosell, E. Carcereny, R. Gervais et al., “Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial,” The Lancet Oncology, vol. 13, no. 3, pp. 239–246, 2012. View at: Publisher Site | Google Scholar
  64. Y. Wang, G. Schmid-Bindert, and C. Zhou, “Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians,” Therapeutic Advances in Medical Oncology, vol. 4, no. 1, pp. 19–29, 2012. View at: Publisher Site | Google Scholar
  65. P. J. Medina and S. Goodin, “Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases,” Clinical Therapeutics, vol. 30, no. 8, pp. 1426–1447, 2008. View at: Publisher Site | Google Scholar
  66. F. Montemurro, G. Valabrega, and M. Aglietta, “Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity,” Expert Opinion on Biological Therapy, vol. 7, no. 2, pp. 257–268, 2007. View at: Publisher Site | Google Scholar
  67. S. Kobayashi, T. J. Boggon, T. Dayaram et al., “EGFR mutation and resistance of non-small-cell lung cancer to gefitinib,” New England Journal of Medicine, vol. 352, no. 8, pp. 786–792, 2005. View at: Publisher Site | Google Scholar
  68. T. Váradi, T. Mersich, P. Auvinen et al., “Binding of trastuzumab to ErbB2 is inhibited by a high pericellular density of hyaluronan,” Journal of Histochemistry and Cytochemistry, vol. 60, no. 8, pp. 567–575, 2012. View at: Publisher Site | Google Scholar
  69. Y. Lu, X. Zi, Y. Zhao, D. Mascarenhas, and M. Pollak, “Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin),” Journal of the National Cancer Institute, vol. 93, no. 24, pp. 1852–1857, 2001. View at: Publisher Site | Google Scholar
  70. S. Venkateswarlu, D. M. Dawson, P. St Clair, A. Gupta, J. K. V. Willson, and M. G. Brattain, “Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells,” Oncogene, vol. 21, no. 1, pp. 78–86, 2002. View at: Publisher Site | Google Scholar
  71. S. M. Swain, J. Baselga, S.-B. Kim et al., “Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer,” The New England Journal of Medicine, vol. 372, no. 8, pp. 724–734, 2015. View at: Publisher Site | Google Scholar
  72. L. De Mattos-Arruda, R. Shen, J. S. Reis-Filho, and J. Cortés, “Translating neoadjuvant therapy into survival benefits: one size does not fit all,” Nature Reviews Clinical Oncology, vol. 13, no. 9, pp. 566–579, 2016. View at: Publisher Site | Google Scholar
  73. J. Cao, J. Han, H. Xiao, J. Qiao, and M. Han, “Effect of tea polyphenol compounds on anticancer drugs in terms of anti-tumor activity, toxicology, and pharmacokinetics,” Nutrients, vol. 8, no. 12, article no. 762, 2016. View at: Publisher Site | Google Scholar
  74. Y.-J. Surh, “Cancer chemoprevention with dietary phytochemicals,” Nature Reviews Cancer, vol. 3, no. 10, pp. 768–780, 2003. View at: Publisher Site | Google Scholar
  75. M.-M. Mocanu, P. Nagy, and J. Szöllosi, “Chemoprevention of breast cancer by dietary polyphenols,” Molecules, vol. 20, no. 12, pp. 22578–22620, 2015. View at: Publisher Site | Google Scholar
  76. R. Kotecha, A. Takami, and J. L. Espinoza, “Dietary phytochemicals and cancer chemoprevention: a review of the clinical evidence,” Oncotarget, vol. 7, no. 32, pp. 52517–52529, 2016. View at: Publisher Site | Google Scholar
  77. M. Fantini, M. Benvenuto, L. Masuelli et al., “In vitro and in vivo antitumoral effects of combinations of polyphenols, or polyphenols and anticancer drugs: perspectives on cancer treatment,” International Journal of Molecular Sciences, vol. 16, no. 5, pp. 9236–9282, 2015. View at: Publisher Site | Google Scholar
  78. J. H. Lee, T. O. Khor, L. Shu, Z.-Y. Su, F. Fuentes, and A.-N. T. Kong, “Dietary phytochemicals and cancer prevention: Nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression,” Pharmacology and Therapeutics, vol. 137, no. 2, pp. 153–171, 2013. View at: Publisher Site | Google Scholar
  79. L. G. Xiong, Y. J. Chen, J. W. Tong et al., “Tea polyphenol epigallocatechin gallate inhibits Escherichia coli by increasing endogenous oxidative stress,” Food Chemistry, vol. 217, pp. 196–204, 2017. View at: Publisher Site | Google Scholar
  80. B. N. Singh, S. Shankar, and R. K. Srivastava, “Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications,” Biochemical Pharmacology, vol. 82, no. 12, pp. 1807–1821, 2011. View at: Publisher Site | Google Scholar
  81. M. Shimizu, Y. Shirakami, and H. Moriwaki, “Targeting receptor tyrosine kinases for chemoprevention by green tea catechin, EGCG,” International Journal of Molecular Sciences, vol. 9, no. 6, pp. 1034–1049, 2008. View at: Publisher Site | Google Scholar
  82. S. Guo, J. Lu, A. Subramanian, and G. E. Sonenshein, “Microarray-assisted pathway analysis identifies mitogen-activated protein kinase signaling as a mediator of resistance to the green tea polyphenol epigallocatechin 3-gallate in Her-2/neu-overexpressing breast cancer cells,” Cancer Research, vol. 66, no. 10, pp. 5322–5329, 2006. View at: Publisher Site | Google Scholar
  83. Y.-C. Liang, S.-Y. Lin-shiau, C.-F. Chen, and J.-K. Lin, “Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells,” Journal of Cellular Biochemistry, vol. 67, no. 1, pp. 55–65, 1997. View at: Publisher Site | Google Scholar
  84. S. Adachi, T. Nagao, H. I. Ingolfsson et al., “The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells,” Cancer Research, vol. 67, no. 13, pp. 6493–6501, 2007. View at: Publisher Site | Google Scholar
  85. S. Adachi, M. Shimizu, Y. Shirakami et al., “(−)-Epigallocatechin gallate downregulates EGF receptor via phosphorylation at Ser1046/1047 by p38 MAPK in colon cancer cells,” Carcinogenesis, vol. 30, no. 9, pp. 1544–1552, 2009. View at: Publisher Site | Google Scholar
  86. M. Komoto, B. Nakata, R. Amano et al., “HER2 overexpression correlates with survival after curative resection of pancreatic cancer,” Cancer Science, vol. 100, no. 7, pp. 1243–1247, 2009. View at: Publisher Site | Google Scholar
  87. S. Liu, X.-J. Wang, Y. Liu, and Y.-F. Cui, “PI3K/AKT/mTOR signaling is involved in (-)-epigallocatechin-3-gallate-induced apoptosis of human pancreatic carcinoma cells,” American Journal of Chinese Medicine, vol. 41, no. 3, pp. 629–642, 2013. View at: Publisher Site | Google Scholar
  88. S.-N. Tang, J. Fu, S. Shankar, and R. K. Srivastava, “EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer,” PLoS ONE, vol. 7, no. 2, Article ID e31067, 2012. View at: Publisher Site | Google Scholar
  89. J. S. Jurenka, “Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research,” Alternative Medicine Review, vol. 14, no. 2, pp. 141–153, 2009. View at: Google Scholar
  90. J. Ravindran, S. Prasad, and B. B. Aggarwal, “Curcumin and cancer cells: how many ways can curry kill tumor cells selectively?” AAPS Journal, vol. 11, no. 3, pp. 495–510, 2009. View at: Publisher Site | Google Scholar
  91. R. K. Maheshwari, A. K. Singh, J. Gaddipati, and R. C. Srimal, “Multiple biological activities of curcumin: a short review,” Life Sciences, vol. 78, no. 18, pp. 2081–2087, 2006. View at: Publisher Site | Google Scholar
  92. J. G. Devassy, I. D. Nwachukwu, and P. J. H. Jones, “Curcumin and cancer: barriers to obtaining a health claim,” Nutrition Reviews, vol. 73, no. 3, pp. 155–165, 2015. View at: Publisher Site | Google Scholar
  93. A. H. Rahmani, M. A. Al Zohairy, S. M. Aly, and M. A. Khan, “Curcumin: a potential candidate in prevention of cancer via modulation of molecular pathways,” BioMed Research International, vol. 2014, Article ID 761608, 15 pages, 2014. View at: Publisher Site | Google Scholar
  94. A. B. Kunnumakkara, P. Anand, and B. B. Aggarwal, “Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins,” Cancer Letters, vol. 269, no. 2, pp. 199–225, 2008. View at: Publisher Site | Google Scholar
  95. K. I. Priyadarsini, “The chemistry of curcumin: from extraction to therapeutic agent,” Molecules, vol. 19, no. 12, pp. 20091–20112, 2014. View at: Publisher Site | Google Scholar
  96. R. L. Hong, W. H. Spohn, and M. C. Hung, “Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu,” Clinical Cancer Research, vol. 5, no. 7, pp. 1884–1891, 1999. View at: Google Scholar
  97. Y. Jung, W. Xu, H. Kim, N. Ha, and L. Neckers, “Curcumin-induced degradation of ErbB2: a role for the E3 ubiquitin ligase CHIP and the Michael reaction acceptor activity of curcumin,” Biochimica et Biophysica Acta - Molecular Cell Research, vol. 1773, no. 3, pp. 383–390, 2007. View at: Publisher Site | Google Scholar
  98. C. Zhou, X.-M. Zhao, X.-F. Li et al., “Curcumin inhibits AP-2γ-induced apoptosis in the human malignant testicular germ cells in vitro,” Acta Pharmacologica Sinica, vol. 34, no. 9, pp. 1192–1200, 2013. View at: Publisher Site | Google Scholar
  99. S. C. Gupta, S. Patchva, W. Koh, and B. B. Aggarwal, “Discovery of curcumin, a component of golden spice, and its miraculous biological activities,” Clinical and Experimental Pharmacology and Physiology, vol. 39, no. 3, pp. 283–299, 2012. View at: Publisher Site | Google Scholar
  100. S. C. Gupta, S. Patchva, and B. B. Aggarwal, “Therapeutic roles of curcumin: lessons learned from clinical trials,” AAPS Journal, vol. 15, no. 1, pp. 195–218, 2013. View at: Publisher Site | Google Scholar
  101. J. Dujic, S. Kippenberger, A. Ramirez-Bosca et al., “Curcumin in combination with visible light inhibits tumor growth in a xenograft tumor model,” International Journal of Cancer, vol. 124, no. 6, pp. 1422–1428, 2009. View at: Publisher Site | Google Scholar
  102. S. Li, Z. Liu, F. Zhu et al., “Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor,” Oncology Research, vol. 21, no. 3, pp. 137–144, 2013. View at: Publisher Site | Google Scholar
  103. T. Dorai, Y.-C. Cao, B. Dorai, R. Buttyan, and A. E. Katz, “Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo,” Prostate, vol. 47, no. 4, pp. 293–303, 2001. View at: Publisher Site | Google Scholar
  104. D. Trudel, D. P. Labbé, M. Araya-Farias et al., “A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer,” Gynecologic Oncology, vol. 131, no. 2, pp. 357–361, 2013. View at: Publisher Site | Google Scholar
  105. J. McLarty, R. L. H. Bigelow, M. Smith, D. Elmajian, M. Ankem, and J. A. Cardelli, “Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro,” Cancer Prevention Research, vol. 2, no. 7, pp. 673–682, 2009. View at: Publisher Site | Google Scholar
  106. A. S. Tsao, D. Liu, J. Martin et al., “Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions,” Cancer Prevention Research, vol. 2, no. 11, pp. 931–941, 2009. View at: Publisher Site | Google Scholar
  107. A. K. Joe, F. Schnoll-Sussman, R. S. Bresalier et al., “Phase Ib randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in patients with Barrett's Esophagus,” Cancer Prevention Research, vol. 8, no. 12, pp. 1131–1137, 2015. View at: Publisher Site | Google Scholar
  108. A. M. Dostal, H. Samavat, S. Bedell et al., “The safety of green tea extract supplementation in postmenopausal women at risk for breast cancer: results of the Minnesota Green Tea Trial,” Food and Chemical Toxicology, vol. 83, pp. 26–35, 2015. View at: Publisher Site | Google Scholar
  109. R. A. Sharma, S. A. Euden, S. L. Platton et al., “Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance,” Clinical Cancer Research, vol. 10, no. 20, pp. 6847–6854, 2004. View at: Publisher Site | Google Scholar
  110. R. E. Carroll, R. V. Benya, D. K. Turgeon et al., “Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia,” Cancer Prevention Research, vol. 4, no. 3, pp. 354–364, 2011. View at: Publisher Site | Google Scholar
  111. M. Kanai, K. Yoshimura, M. Asada et al., “A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer,” Cancer Chemotherapy and Pharmacology, vol. 68, no. 1, pp. 157–164, 2011. View at: Publisher Site | Google Scholar
  112. R. Epelbaum, M. Schaffer, B. Vizel, V. Badmaev, and G. Bar-Sela, “Curcumin and gemcitabine in patients with advanced pancreatic cancer,” Nutrition and Cancer, vol. 62, no. 8, pp. 1137–1141, 2010. View at: Publisher Site | Google Scholar
  113. M. Bayet-Robert, F. Kwiatkowski, M. Leheurteur et al., “Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer,” Cancer Biology and Therapy, vol. 9, no. 1, pp. 8–14, 2010. View at: Google Scholar
  114. A. H. Lee, D. Su, M. Pasalich, and C. W. Binns, “Tea consumption reduces ovarian cancer risk,” Cancer Epidemiology, vol. 37, no. 1, pp. 54–59, 2013. View at: Publisher Site | Google Scholar
  115. T. Makiuchi, T. Sobue, T. Kitamura et al., “Association between green tea/coffee consumption and biliary tract cancer: a population-based cohort study in Japan,” Cancer Science, vol. 107, no. 1, pp. 76–83, 2016. View at: Publisher Site | Google Scholar
  116. C. Bamia, P. Lagiou, M. Jenab et al., “Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a European population: multicentre, prospective cohort study,” International Journal of Cancer, vol. 136, no. 8, pp. 1899–1908, 2015. View at: Publisher Site | Google Scholar
  117. L. Chen, M.-J. Lee, H. Li, and C. S. Yang, “Absorption, distribution, and elimination of tea polyphenols in rats,” Drug Metabolism and Disposition, vol. 25, no. 9, pp. 1045–1050, 1997. View at: Google Scholar
  118. Y. Oritani, Y. Setoguchi, R. Ito, H. Maruki-Uchida, T. Ichiyanagi, and T. Ito, “Comparison of (-)-epigallocatechin-3-O-gallate (EGCG) and O-methyl EGCG bioavailability in rats,” Biological and Pharmaceutical Bulletin, vol. 36, no. 10, pp. 1577–1582, 2013. View at: Publisher Site | Google Scholar
  119. J. D. Lambert, M.-J. Lee, H. Lu et al., “Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice,” The Journal of Nutrition, vol. 133, no. 12, pp. 4172–4177, 2003. View at: Google Scholar
  120. J. D. Lambert, J. Hong, D. H. Kim, V. M. Mishin, and C. S. Yang, “Piperine enhances the bioavailability of the tea polyphenol (-)-epigallocatechin-3-gallate in mice,” Journal of Nutrition, vol. 134, no. 8, pp. 1948–1952, 2004. View at: Google Scholar
  121. C. M. Peters, R. J. Green, E. M. Janle, and M. G. Ferruzzi, “Formulation with ascorbic acid and sucrose modulates catechin bioavailability from green tea,” Food Research International, vol. 43, no. 1, pp. 95–102, 2010. View at: Publisher Site | Google Scholar
  122. J. D. Lambert, S.-J. Kwon, J. Ju et al., “Effect of genistein on the bioavailability and intestinal cancer chemopreventive activity of (-)-epigallocatechin-3-gallate,” Carcinogenesis, vol. 29, no. 10, pp. 2019–2024, 2008. View at: Publisher Site | Google Scholar
  123. M. Suganuma, S. Okabe, M. Oniyama, Y. Tada, H. Ito, and H. Fujiki, “Wide distribution of [3H](-)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue,” Carcinogenesis, vol. 19, no. 10, pp. 1771–1776, 1998. View at: Publisher Site | Google Scholar
  124. K. D. James, S. C. Forester, and J. D. Lambert, “Dietary pretreatment with green tea polyphenol, (−)-epigallocatechin-3-gallate reduces the bioavailability and hepatotoxicity of subsequent oral bolus doses of (−)-epigallocatechin-3-gallate,” Food and Chemical Toxicology, vol. 76, pp. 103–108, 2015. View at: Publisher Site | Google Scholar
  125. K. Landis-Piwowar, D. Chen, T. H. Chan, and Q. P. Dou, “Inhibition of catechol-O-methyltransferase activity in human breast cancer cells enhances the biological effect of the green tea polyphenol (-)-EGCG,” Oncology Reports, vol. 24, no. 2, pp. 563–569, 2010. View at: Publisher Site | Google Scholar
  126. P. Wang, D. Heber, and S. M. Henning, “Quercetin increased bioavailability and decreased methylation of green tea polyphenols in vitro and in vivo,” Food and Function, vol. 3, no. 6, pp. 635–642, 2012. View at: Publisher Site | Google Scholar
  127. P. Wang, W. J. Aronson, M. Huang et al., “Green tea polyphenols and metabolites in prostatectomy tissue: implications for cancer prevention,” Cancer Prevention Research, vol. 3, no. 8, pp. 985–993, 2010. View at: Publisher Site | Google Scholar
  128. V. Crespy, N. Nancoz, M. Oliveira, J. Hau, M.-C. Courtet-Compondu, and G. Williamson, “Glucuronidation of the green tea catechins, (-)-epigallocatechin-3-gallate and (-)-epicatechin-3-gallate, by rat hepatic and intestinal microsomes,” Free Radical Research, vol. 38, no. 9, pp. 1025–1031, 2004. View at: Publisher Site | Google Scholar
  129. M.-J. Lee, P. Maliakal, L. Chen et al., “Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability,” Cancer Epidemiology Biomarkers and Prevention, vol. 11, no. 10, pp. 1025–1032, 2002. View at: Google Scholar
  130. H.-H. S. Chow, Y. Cai, D. S. Alberts et al., “Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and Polyphenon E,” Cancer Epidemiology Biomarkers and Prevention, vol. 10, no. 1, pp. 53–58, 2001. View at: Google Scholar
  131. K. Nakagawa, K. Nakayama, M. Nakamura et al., “Effects of co-administration of tea epigallocatechin-3-gallate (EGCG) and caffeine on absorption and metabolism of EGCG in humans,” Bioscience, Biotechnology and Biochemistry, vol. 73, no. 9, pp. 2014–2017, 2009. View at: Publisher Site | Google Scholar
  132. C. D. Lao, M. T. Ruffin IV, D. Normolle et al., “Dose escalation of a curcuminoid formulation,” BMC Complementary and Alternative Medicine, vol. 6, article no. 10, 2006. View at: Publisher Site | Google Scholar
  133. Y.-M. Tsai, C.-F. Chien, L.-C. Lin, and T.-H. Tsai, “Curcumin and its nano-formulation: the kinetics of tissue distribution and blood-brain barrier penetration,” International Journal of Pharmaceutics, vol. 416, no. 1, pp. 331–338, 2011. View at: Publisher Site | Google Scholar
  134. N. K. Gupta and V. K. Dixit, “Bioavailability enhancement of curcumin by complexation with phosphatidyl choline,” Journal of Pharmaceutical Sciences, vol. 100, no. 5, pp. 1987–1995, 2011. View at: Publisher Site | Google Scholar
  135. S. Manju and K. Sreenivasan, “Conjugation of curcumin onto hyaluronic acid enhances its aqueous solubility and stability,” Journal of Colloid and Interface Science, vol. 359, no. 1, pp. 318–325, 2011. View at: Publisher Site | Google Scholar
  136. J. Li, Y. Wang, C. Yang et al., “Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1,” Molecular Pharmacology, vol. 76, no. 1, pp. 81–90, 2009. View at: Publisher Site | Google Scholar
  137. S. Debnath, D. Saloum, S. Dolai et al., “Dendrimer-curcumin conjugate: a water soluble and effective cytotoxic agent against breast cancer cell lines,” Anti-Cancer Agents in Medicinal Chemistry, vol. 13, no. 10, pp. 1531–1539, 2013. View at: Publisher Site | Google Scholar
  138. L. Hu, Y. Jia, F. Niu, Z. Jia, X. Yang, and K. Jiao, “Preparation and enhancement of oral bioavailability of curcumin using microemulsions vehicle,” Journal of Agricultural and Food Chemistry, vol. 60, no. 29, pp. 7137–7141, 2012. View at: Publisher Site | Google Scholar
  139. A. M. Chuah, B. Jacob, Z. Jie et al., “Enhanced bioavailability and bioefficacy of an amorphous solid dispersion of curcumin,” Food Chemistry, vol. 156, pp. 227–233, 2014. View at: Publisher Site | Google Scholar
  140. J. M. Reid, S. A. Buhrow, J. A. Gilbert et al., “Mouse pharmacokinetics and metabolism of the curcumin analog, 4-piperidinone,3,5-bis[(2-fluorophenyl)methylene]-acetate(3E,5E) (EF-24; NSC 716993),” Cancer Chemotherapy and Pharmacology, vol. 73, no. 6, pp. 1137–1146, 2014. View at: Publisher Site | Google Scholar
  141. K. Mohankumar, S. Sridharan, S. Pajaniradje et al., “BDMC-A, an analog of curcumin, inhibits markers of invasion, angiogenesis, and metastasis in breast cancer cells via NF-κB pathway—a comparative study with curcumin,” Biomedicine and Pharmacotherapy, vol. 74, pp. 178–186, 2015. View at: Publisher Site | Google Scholar
  142. C. Kudo, H. Yamakoshi, A. Sato et al., “Synthesis of 86 species of 1,5-diaryl-3-oxo-1,4-pentadienes analogs of curcumin can yield a good lead in vivo,” BMC Pharmacology, vol. 11, article 4, 2011. View at: Publisher Site | Google Scholar
  143. L. Hackler Jr., B. Ózsvári, M. Gyuris et al., “The curcumin analog C-150, influencing NF-κB, UPR and Akt/Notch pathways has potent anticancer activity in vitro and in vivo,” PLoS ONE, vol. 11, no. 3, Article ID e0149832, 2016. View at: Publisher Site | Google Scholar
  144. S. B. Subramanian, A. P. Francis, and T. Devasena, “Chitosan-starch nanocomposite particles as a drug carrier for the delivery of bis-desmethoxy curcumin analog,” Carbohydrate Polymers, vol. 114, pp. 170–178, 2014. View at: Publisher Site | Google Scholar
  145. C. R. Ireson, D. J. L. Jones, S. Orr et al., “Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine,” Cancer Epidemiology Biomarkers and Prevention, vol. 11, no. 1, pp. 105–111, 2002. View at: Google Scholar
  146. O. N. Gordon, P. B. Luis, H. O. Sintim, and C. Schneider, “Unraveling curcumin degradation: autoxidation proceeds through spiroepoxide and vinylether intermediates en route to the main bicyclopentadione,” The Journal of Biological Chemistry, vol. 290, no. 8, pp. 4817–4828, 2015. View at: Publisher Site | Google Scholar
  147. M. Griesser, V. Pistis, T. Suzuki, N. Tejera, D. A. Pratt, and C. Schneider, “Autoxidative and cyclooxygenase-2 catalyzed transformation of the dietary chemopreventive agent curcumin,” Journal of Biological Chemistry, vol. 286, no. 2, pp. 1114–1124, 2011. View at: Publisher Site | Google Scholar
  148. M. Heger, R. F. van Golen, M. Broekgaarden, and M. C. Michel, “The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancers,” Pharmacological Reviews, vol. 66, no. 1, pp. 222–307, 2014. View at: Publisher Site | Google Scholar
  149. R. A. Sharma, H. R. McLelland, K. A. Hill et al., “Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer,” Clinical Cancer Research, vol. 7, no. 7, pp. 1894–1900, 2001. View at: Google Scholar
  150. M. Kanai, A. Imaizumi, Y. Otsuka et al., “Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers,” Cancer Chemotherapy and Pharmacology, vol. 69, no. 1, pp. 65–70, 2012. View at: Publisher Site | Google Scholar
  151. H. Sasaki, Y. Sunagawa, K. Takahashi et al., “Innovative preparation of curcumin for improved oral bioavailability,” Biological and Pharmaceutical Bulletin, vol. 34, no. 5, pp. 660–665, 2011. View at: Publisher Site | Google Scholar
  152. S. Prasad, A. K. Tyagi, and B. B. Aggarwal, “Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice,” Cancer Research and Treatment, vol. 46, no. 1, pp. 2–18, 2014. View at: Publisher Site | Google Scholar
  153. G. Shoba, D. Joy, T. Joseph, M. Majeed, R. Rajendran, and P. S. S. R. Srinivas, “Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers,” Planta Medica, vol. 64, no. 4, pp. 353–356, 1998. View at: Publisher Site | Google Scholar
  154. N. M. Yunos, P. Beale, J. Q. Yu, and F. Huq, “Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells,” Anticancer Research, vol. 31, no. 4, pp. 1131–1140, 2011. View at: Google Scholar
  155. N. M. Yunos, P. Beale, J. Q. Yu, and F. Huq, “Synergism from the combination of oxaliplatin with selected phytochemicals in human ovarian cancer cell lines,” Anticancer Research, vol. 31, no. 12, pp. 4283–4289, 2011. View at: Google Scholar
  156. F. Hu, F. Wei, Y. Wang, B. Wu, Y. Fang, and B. Xiong, “EGCG synergizes the therapeutic effect of cisplatin and oxaliplatin through autophagic pathway in human colorectal cancer cells,” Journal of Pharmacological Sciences, vol. 128, no. 1, pp. 27–34, 2015. View at: Publisher Site | Google Scholar
  157. K. Selvendiran, S. Ahmed, A. Dayton et al., “HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition,” Cancer Biology & Therapy, vol. 12, no. 9, pp. 837–845, 2011. View at: Publisher Site | Google Scholar
  158. A. R. M. Ruhul Amin, D. Wang, H. Zhang et al., “Enhanced anti-tumor activity by the combination of the natural compounds (−)-epigallocatechin-3-gallate and luteolin: potential role of p53,” Journal of Biological Chemistry, vol. 285, no. 45, pp. 34557–34565, 2010. View at: Publisher Site | Google Scholar
  159. T.-C. Hsieh and J. M. Wu, “Suppression of cell proliferation and gene expression by combinatorial synergy of EGCG, resveratrol and γ-tocotrienol in estrogen receptor-positive MCF-7 breast cancer cells,” International Journal of Oncology, vol. 33, no. 4, pp. 851–859, 2008. View at: Publisher Site | Google Scholar
  160. T.-C. Hsieh and J. M. Wu, “Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin,” Anticancer Research, vol. 29, no. 10, pp. 4025–4032, 2009. View at: Google Scholar
  161. F. Ye, G.-H. Zhang, B.-X. Guan, and X.-C. Xu, “Suppression of esophageal cancer cell growth using curcumin, (-)-epigallocatechin-3-gallate and lovastatin,” World Journal of Gastroenterology, vol. 18, no. 2, pp. 126–135, 2012. View at: Publisher Site | Google Scholar
  162. S. S. Chung and J. V. Vadgama, “Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling,” Anticancer Research, vol. 35, no. 1, pp. 39–46, 2015. View at: Google Scholar
  163. Q. Du, B. Hu, H.-M. An et al., “Synergistic anticancer effects of curcumin and resveratrol in Hepa1-6 hepatocellular carcinoma cells,” Oncology Reports, vol. 29, no. 5, pp. 1851–1858, 2013. View at: Publisher Site | Google Scholar
  164. T. J. Somers-Edgar, M. J. Scandlyn, E. C. Stuart, M. J. Le Nedelec, S. P. Valentine, and R. J. Rosengren, “The combination of epigallocatechin gallate and curcumin suppresses ERα-breast cancer cell growth in vitro and in vivo,” International Journal of Cancer, vol. 122, no. 9, pp. 1966–1971, 2008. View at: Publisher Site | Google Scholar
  165. D.-H. Zhou, X. Wang, M. Yang, X. Shi, W. Huang, and Q. Feng, “Combination of low concentration of (−)-epigallocatechin gallate (EGCG) and curcumin strongly suppresses the growth of non-small cell lung cancer in vitro and in vivo through causing cell cycle arrest,” International Journal of Molecular Sciences, vol. 14, no. 6, pp. 12023–12036, 2013. View at: Publisher Site | Google Scholar
  166. M. Masuda, T. Wakasaki, S. Toh, M. Shimizu, and S. Adachi, “Chemoprevention of head and neck cancer by green tea extract: EGCG—the role of EGFR signaling and ‘lipid raft’,” Journal of Oncology, vol. 2011, Article ID 540148, 7 pages, 2011. View at: Publisher Site | Google Scholar
  167. M.-M. Mocanu, C. Ganea, L. Georgescu et al., “Epigallocatechin 3-O-gallate induces 67 kDa laminin receptor-mediated cell death accompanied by downregulation of ErbB proteins and altered lipid raft clustering in mammary and epidermoid carcinoma cells,” Journal of Natural Products, vol. 77, no. 2, pp. 250–257, 2014. View at: Publisher Site | Google Scholar
  168. H. Huynh, T. T. Nguyen, E. Chan, and E. Tran, “Inhibition of ErbB-2 and ErbB-3 expression by quercetin prevents transforming growth factor alpha (TGF-α)- and epidermal growth factor (EGF)-induced human PC-3 prostate cancer cell proliferation,” International Journal of Oncology, vol. 23, no. 3, pp. 821–829, 2003. View at: Publisher Site | Google Scholar
  169. D. Fridrich, N. Teller, M. Esselen, G. Pahlke, and D. Marko, “Comparison of delphinidin, quercetin and (-)-epigallocatechin-3-gallate as inhibitors of the EGFR and the ErbB2 receptor phosphorylation,” Molecular Nutrition and Food Research, vol. 52, no. 7, pp. 815–822, 2008. View at: Publisher Site | Google Scholar
  170. J.-Y. Lee, Y.-M. Lee, G.-C. Chang et al., “Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy,” PLoS ONE, vol. 6, no. 8, Article ID e23756, 2011. View at: Publisher Site | Google Scholar
  171. A. Khan, A. N. Aljarbou, Y. H. Aldebasi, S. M. Faisal, and M. A. Khan, “Resveratrol suppresses the proliferation of breast cancer cells by inhibiting fatty acid synthase signaling pathway,” Cancer Epidemiology, vol. 38, no. 6, pp. 765–772, 2014. View at: Publisher Site | Google Scholar
  172. T.-D. Way, M.-C. Kao, and J.-K. Lin, “Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway,” The Journal of Biological Chemistry, vol. 279, no. 6, pp. 4479–4489, 2004. View at: Publisher Site | Google Scholar
  173. N. Dhillon, B. B. Aggarwal, R. A. Newman et al., “Phase II trial of curcumin in patients with advanced pancreatic cancer,” Clinical Cancer Research, vol. 14, no. 14, pp. 4491–4499, 2008. View at: Publisher Site | Google Scholar
  174. J. C. Montero, S. García-Alonso, A. Ocaña, and A. Pandiella, “Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling,” Oncotarget, vol. 6, no. 30, pp. 30057–30071, 2015. View at: Publisher Site | Google Scholar
  175. K. Subik, J.-F. Lee, L. Baxter et al., “The expression patterns of ER, PR, HER2, CK5/6, EGFR, KI-67 and AR by immunohistochemical analysis in breast cancer cell lines,” Breast Cancer: Basic and Clinical Research, vol. 4, no. 1, pp. 35–41, 2010. View at: Google Scholar
  176. S. Li, E. Buchbinder, L. Wu et al., “EGFR and HER2 levels are frequently elevated in colon cancer cells,” Discoveries Reports, vol. 1, no. 1, pp. 1–8, 2014. View at: Publisher Site | Google Scholar
  177. J.-I. Okano, I. Gaslightwala, M. J. Birnbaum, A. K. Rustgi, and H. Nakagawa, “Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation,” The Journal of Biological Chemistry, vol. 275, no. 40, pp. 30934–30942, 2000. View at: Publisher Site | Google Scholar
  178. S. Song, S. Honjo, J. Jin et al., “The hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer,” Clinical Cancer Research, vol. 21, no. 11, pp. 2580–2590, 2015. View at: Publisher Site | Google Scholar
  179. P. Huang, X. Xu, L. Wang, B. Zhu, X. Wang, and J. Xia, “The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment,” Journal of Cellular and Molecular Medicine, vol. 18, no. 2, pp. 218–230, 2014. View at: Publisher Site | Google Scholar
  180. S.-S. Guan, J. Chang, C.-C. Cheng et al., “Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo,” Oncotarget, vol. 5, no. 13, pp. 4868–4880, 2014. View at: Publisher Site | Google Scholar
  181. Y. Wang, T. Romigh, X. He et al., “Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines,” Human Molecular Genetics, vol. 19, no. 22, pp. 4319–4329, 2010. View at: Publisher Site | Google Scholar
  182. G. M. Seigel, S. Sharma, A. S. Hackam, and D. K. Shah, “HER2/ERBB2 immunoreactivity in human retinoblastoma,” Tumor Biology, vol. 37, no. 5, pp. 6135–6142, 2016. View at: Publisher Site | Google Scholar
  183. S. Sreenivasan and S. Krishnakumar, “Synergistic effect of curcumin in combination with anticancer agents in human retinoblastoma cancer cell lines,” Current Eye Research, vol. 40, no. 11, pp. 1153–1165, 2015. View at: Publisher Site | Google Scholar
  184. A. Montgomery, T. Adeyeni, K. San, R. M. Heuertz, and U. R. Ezekiel, “Curcumin sensitizes silymarin to exert synergistic anticancer activity in colon cancer cells,” Journal of Cancer, vol. 7, no. 10, pp. 1250–1257, 2016. View at: Publisher Site | Google Scholar
  185. W. P. Tsang and T. T. Kwok, “Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells,” Journal of Nutritional Biochemistry, vol. 21, no. 2, pp. 140–146, 2010. View at: Publisher Site | Google Scholar
  186. D. Milenkovic, B. Jude, and C. Morand, “miRNA as molecular target of polyphenols underlying their biological effects,” Free Radical Biology and Medicine, vol. 64, pp. 40–51, 2013. View at: Publisher Site | Google Scholar
  187. Y. Tutar, “miRNA and cancer; computational and experimental approaches,” Current Pharmaceutical Biotechnology, vol. 15, no. 5, p. 429, 2014. View at: Publisher Site | Google Scholar
  188. M. Sun, Z. Estrov, Y. Ji, K. R. Coombes, D. H. Harris, and R. Kurzrock, “Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells,” Molecular Cancer Therapeutics, vol. 7, no. 3, pp. 464–473, 2008. View at: Publisher Site | Google Scholar
  189. S. Toden, Y. Okugawa, T. Jascur et al., “Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer,” Carcinogenesis, vol. 36, no. 3, pp. 355–367, 2015. View at: Publisher Site | Google Scholar

Copyright © 2017 Alexandru Filippi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.